Read by QxMD icon Read

Multicenter radiotherapy

P Sargos, T Charleux, R L Haas, A Michot, C Llacer, L Moureau-Zabotto, G Vogin, C Le Péchoux, C Verry, A Ducassou, M Delannes, A Mervoyer, N Wiazzane, J Thariat, M P Sunyach, M Benchalal, J D Laredo, M Kind, P Gillon, G Kantor
PURPOSE: The purpose of this study was to evaluate, during a national workshop, the inter-observer variability in target volume delineation for primary extremity soft tissue sarcoma radiation therapy. METHODS AND MATERIALS: Six expert sarcoma radiation oncologists (members of French Sarcoma Group) received two extremity soft tissue sarcoma radiation therapy cases 1: one preoperative and one postoperative. They were distributed with instructions for contouring gross tumour volume or reconstructed gross tumour volume, clinical target volume and to propose a planning target volume...
March 12, 2018: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
Anas Nooh, Krista Goulding, Marc H Isler, Sophie Mottard, Annie Arteau, Norbert Dion, Robert Turcotte
BACKGROUND: Bone metastases represent the most frequent cause of cancer-related pain, affecting health-related quality of life and creating a substantial burden on the healthcare system. Although most bony metastatic lesions can be managed nonoperatively, surgical management can help patients reduce severe pain, avoid impending fracture, and stabilize pathologic fractures. Studies have demonstrated functional improvement postoperatively as early as 6 weeks, but little data exist on the temporal progress of these improvements or on the changes in quality of life over time as a result of surgical intervention...
March 2018: Clinical Orthopaedics and related Research
Jens Overgaard, Camilla Molich Hoff, Hanne Sand Hansen, Lena Specht, Marie Overgaard, Pernille Lassen, Elo Andersen, Jørgen Johansen, Lisbeth Juhler Andersen, Jan Folkvard Evensen, Jan Alsner, Cai Grau
PURPOSE: To evaluate if correction of low hemoglobin (Hb) levels by means of darbepoetin alfa improves the outcomes of radiotherapy in patients with squamous cell carcinoma of the head and neck (HNSCC). PATIENTS AND METHODS: Patients eligible for primary radiotherapy and who had Hb values below 14.0 g/dl were randomized to receive accelerated fractionated radiotherapy with or without darbepoetin alfa. Patients also received the hypoxic radiosensitizer nimorazole...
March 6, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Katsuya Sugizaki, Akira Tari, Yasuhiko Kitadai, Ichiro Oda, Shotaro Nakamura, Tadashi Yoshino, Toshiro Sugiyama
BACKGROUND: Helicobacter pylori eradication therapy was approved in Japan for the first-line, standard treatment of H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small-scale single-center studies have been reported, a prospective, large-scale, nationwide, multicenter study has not been reported from Japan. MATERIALS AND METHODS: We conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole-based triple H...
March 4, 2018: Helicobacter
Shulian Wang, Jeff Campbell, Matthew H Stenmark, Paul Stanton, Jing Zhao, Martha M Matuszak, Randall K Ten Haken, Feng-Ming Kong
BACKGROUND AND PURPOSE: To study whether cytokine markers may improve predictive accuracy of radiation esophagitis (RE) in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: A total of 129 patients with stage I-III NSCLC treated with radiotherapy (RT) from prospective studies were included. Thirty inflammatory cytokines were measured in platelet-poor plasma samples. Logistic regression was performed to evaluate the risk factors of RE. Stepwise Akaike information criterion (AIC) and likelihood ratio test were used to assess model predictions...
February 26, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
R C Melchers, R Willemze, M W Bekkenk, E R M de Haas, B Horvath, M M van Rossum, C J G Sanders, J C J M Veraart, M H Vermeer, K D Quint
BACKGROUND: There is no consensus on the treatment of multifocal primary cutaneous anaplastic large cell lymphoma (C-ALCL). Radiotherapy (RT) and methotrexate (MTX) are the current treatment options, but their efficacy is unknown. Recently, targeted therapies showed promising results in C-ALCL, and may therefore be an attractive first choice of treatment. OBJECTIVES: To assess the efficacy of conventional treatment strategies for patients with multifocal C-ALCL, and to define which patients may require novel targeted therapies...
March 1, 2018: British Journal of Dermatology
Kazuhiko Hayashi, Masashi Koto, Yusuke Demizu, Jun-Ichi Saitoh, Hiroaki Suefuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Hiroaki Ikawa, Kenji Nemoto, Takashi Nakano, Tadashi Kamada
A retrospective multicenter study was conducted to assess the clinical outcomes of carbon-ion radiotherapy for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We evaluated the safety and efficacy of carbon-ion radiotherapy in patients with major salivary gland carcinoma. Sixty-nine patients treated with carbon-ion radiotherapy at 4 Japanese institutions were analyzed. Thirty-three patients (48%) had adenoid cystic carcinomas, 10 (14%) had mucoepidermoid carcinomas, and 26 (38%) had other disease types...
March 1, 2018: Cancer Science
Charlotte Demoor, Stéphane Supiot, Marc-André Mahé, Odile Oberlin, Rodrigue Allodji, Nadia Haddy, Sylvie Helfre, Celine Vigneron, Valérie Brillaud-Meflah, Balérie Bernier, Anne Laprie, Anne Ducassou, Line Claude, Ibrahim Diallo, Florent de Vathaire
OBJECTIVE: The purpose of this study was to determine the characteristics of early second breast cancer (SBC) among survivors of childhood and young adult malignancy treated with irradiation. METHODS: We conducted a multicenter retrospective study of women who presented with breast cancer aged 50 years or younger in nine French centers. RESULTS: One hundred and twenty one patients and 141 SBC were analyzed (invasive = 130; non invasive = 11)...
March 1, 2018: British Journal of Radiology
Hiroaki Suefuji, Masashi Koto, Yusuke Demizu, Jun-Ichi Saitoh, Yoshiyuki Shioyama, Hiroshi Tsuji, Tomoaki Okimoto, Tatsuya Ohno, Kenji Nemoto, Takashi Nakano, Tadashi Kamada
The purpose was to evaluate efficacy and safety of carbon ion radiotherapy (C-ion RT) in patients with locally advanced olfactory neuroblastomas (ONBs). This study was a sub-analysis of the Japan Carbon-Ion Radiation Oncology Study Group Study (1402 HN, UMIN000024473). Clinical data of T4 ONBs treated with C-ion RT at four Institutions between November 2003 and December 2014 were retrospectively reviewed. Twenty-one patients underwent C-ion RT. Seven patients had T4a and 14 had T4b tumours without cervical node metastases...
March 2018: Anticancer Research
Robert El-Haddad, Béatrice Lafarge-Claoue, Charles Garabedian, Sylvain Staub
Objective: Observational studies are essential for ensuring patient safety, decreasing complications, and developing better surgical techniques and implants. The primary objective of this study is to demonstrate the safety and efficacy of Sebbin breast implants in both augmentation and reconstruction cohorts. Methods: This prospective, multicenter, observational 10-year study conducted in France included 205 patients (385 implants) who underwent breast augmentation (n = 166) or reconstruction (n = 39) with Sebbin round silicone gel implants...
2018: Eplasty
Yun Chen, Zhengfei Zhu, Weixin Zhao, Ling Li, Jinjun Ye, Chaoyang Wu, Huarong Tang, Qin Lin, Jiancheng Li, Yi Xia, Yunhai Li, Jialiang Zhou, Kuaile Zhao
BACKGROUND: Concurrent chemoradiotherapy is a standard modality for locally advanced esophageal squamous cell carcinoma (ESCC) patients. Cisplatin combined with 5-fluorouracil continuous infusion (PF) remains the standard concurrent chemotherapy regimen. However, radiotherapy concurrent with PF showed a high incidence of severe side effects. Paclitaxel showed a promising radiosensitivity enhancement in the treatment of esophageal carcinoma in both vitro and vivo studies. The ESO-Shanghai 1 trial examines the hypothesis that paclitaxel plus 5-fluorouracil (TF) concurrent with radiotherapy has better overall survival and lower toxicity for patients with local advanced ESCC...
February 27, 2018: Radiation Oncology
Laila König, Juliane Hörner-Rieber, Denise Bernhardt, Adriane Hommertgen, Stefan Rieken, Jürgen Debus, Klaus Herfarth
PURPOSE: Retrospective study of effectiveness, toxicity, and relapse patterns after low-dose radiotherapy (LDRT) in patients with low-grade lymphomas. METHODS: 47 patients (median age 64 years) with 50 lesions were treated with LDRT (2 × 2 Gy). In 60%, LDRT was the primary and curative treatment, in 40% offered as second-line therapy in recurrent disease. Histology included follicular (57%) and marginal zone lymphomas (43%). Patients were followed-up regularly clinically (skin) and with CT or MRI scans...
February 15, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Andres Huertas, Isabelle Dumas, Alexandre Escande, Eleonor Rivin Del Campo, Tony Felefly, Charles-Henri Canova, Anne Tailleur, Sebastien Gouy, Enrica Bentivegna, Philippe Morice, Christine Haie-Meder, Cyrus Chargari, Renaud Mazeron
PURPOSE: Primary vaginal cancer is a rare disease for which treatment has been modeled based on cervical cancer. We report our experience in the use of image-guided adaptive brachytherapy (IGABT) in this indication. METHODS AND MATERIALS: Patients treated for vaginal cancer with a combination of external beam radiation therapy and IGABT were identified through electronic search. The Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology recommendations for cervical cancer have been extrapolated with the definition of two clinical target volumes (CTVs) corresponding to the residual disease after external beam radiation therapy (CTVBT ), assessed from clinical and imaging findings, and the so-called CTVi , comprising the CTVBT with directional margins and at least the initial disease at diagnosis...
February 6, 2018: Brachytherapy
K A Lee, M Dunne, C Small, P J Kelly, O McArdle, J O'Sullivan, D Hacking, M Pomeroy, J Armstrong, M Moriarty, A Clayton-Lea, I Parker, C D Collins, P Thirion
BACKGROUND: The optimal primary external beam radiation therapy (EBRT) radiation schedule for malignant epidural spinal cord compression (MSCC) remains to be determined. The ICORG 05-03 trial assessed if a 10 Gy single fraction radiation schedule was not inferior to one with 20 Gray (Gy) in five daily fractions, in terms of functional motor outcome, for the treatment of MSCC in patients not proceeding with surgical decompression. This article reports on two of the secondary endpoints, Quality of life (QoL), assessed according to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) version 3...
February 8, 2018: Acta Oncologica
Lode J Swinnen, Anne O'Neill, Philip H Imus, Sachin Gujar, David Schiff, Lawrence R Kleinberg, Ranjana H Advani, Erin M Dunbar, Dennis Moore, Stuart A Grossman
Background: Therapy of primary CNS lymphoma (PCNSL) has focused on multi-agent chemotherapy designed to cross the blood brain barrier. Rituximab has demonstrated activity in PCNSL. E1F05 is an ECOG-ACRIN multicenter phase 2 prospective trial of rituximab with high-dose methotrexate (HD-MTX)-based chemotherapy similar to the RTOG 93-10 regimen, omitting radiotherapy. Methods: Immunocompetent patients with newly diagnosed PCNSL received HD-MTX 3.5g/m2 with vincristine every two weeks for 5 doses; procarbazine for 7 days in weeks 1, 5, and 9; cytarabine 3g/m2/day IV for 2 days in weeks 11 and 14; a dexamethasone taper over 6 weeks; and rituximab 375mg/m2 IV infusion 3 times per week for weeks 1-4...
January 2, 2018: Oncotarget
Jacques Grill, Maura Massimino, Eric Bouffet, Amedeo A Azizi, Geoffrey McCowage, Adela Cañete, Frank Saran, Marie-Cécile Le Deley, Pascale Varlet, Paul S Morgan, Tim Jaspan, Chris Jones, Felice Giangaspero, Helen Smith, Josep Garcia, Markus C Elze, Raphaël F Rousseau, Lauren Abrey, Darren Hargrave, Gilles Vassal
Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (HGG). Methods The randomized, parallel group, multicenter, open-label HERBY trial ( identifier: NCT01390948) enrolled patients age ≥ 3 years to ≤ 18 years with localized, centrally neuropathology-confirmed, nonbrainstem HGG. Eligible patients were randomly assigned to receive RT + TMZ (RT: 1...
February 7, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Anne L Versteeg, Arjun Sahgal, Laurence D Rhines, Daniel M Sciubba, James M Schuster, Michael H Weber, Peter Pal Varga, Stefano Boriani, Chetan Bettegowda, Michael G Fehlings, Michelle J Clarke, Paul M Arnold, Ziya L Gokaslan, Charles G Fisher
BACKGROUND: The Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ) was developed as the first spine oncology-specific health-related quality of life (HRQOL) measure. This study evaluated the psychometric properties and clinical validity of the SOSGOQ in a diverse cohort of patients with spinal metastases. METHODS: An international, multicenter, prospective observational cohort study including patients with spinal metastases who underwent surgery and/or radiotherapy was conducted by the AOSpine Knowledge Forum Tumor...
February 6, 2018: Cancer
Keigo Kobayashi, Ichiro Nakachi, Katsuhiko Naoki, Ryosuke Satomi, Morio Nakamura, Takashi Inoue, Hiroki Tateno, Fumio Sakamaki, Koichi Sayama, Takeshi Terashima, Hidefumi Koh, Takayuki Abe, Makoto Nishino, Daisuke Arai, Hiroyuki Yasuda, Ichiro Kawada, Kenzo Soejima, Tomoko Betsuyaku
BACKGROUND: Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for previously treated advanced non-small-cell lung cancer based on the results from phase III clinical trials. We evaluated the real-world efficacy and safety of nivolumab in a nonselected population and identified the clinical characteristics that influence efficacy. MATERIALS AND METHODS: A total of 142 patients with advanced non-small-cell lung cancer who were administered nivolumab at Keio University and affiliated hospitals in Japan from January to July 2016 were enrolled...
January 5, 2018: Clinical Lung Cancer
Jie Li, Youling Gong, Peng Diao, Qingmei Huang, Yixue Wen, Binwei Lin, Hongwei Cai, Honggang Tian, Bing He, Lanlan Ji, Ping Guo, Jidong Miao, Xiaobo Du
BACKGROUND: Some Chinese patients with esophageal squamous cell carcinomaare often treated with single-agent concurrent chemoradiotherapy. However, no results have been reported from randomized controlled clinical trials comparing single-agent with double-agent concurrent chemoradiotherapy. It therefore remains unclear whether these regimens are equally clinically effective. In this study, we retrospectively analyzed and compared the therapeutic effects of single-agent and double-agent concurrent chemoradiotherapy in patients with unresectable esophageal squamous cell carcinoma...
January 22, 2018: Radiation Oncology
Hussain Alquraini, Maria Del Pilar Schneider, Beloo Mirakhur, Ariel Barkan
PURPOSE: In clinical research involving acromegalic patients naïve to somatostatin-receptor ligands (SRLs), 19 and 31% of those receiving the SRLs octreotide LAR and pasireotide LAR, respectively, achieved GH < 2.5 ng/mL + normalized IGF-1 concentrations. The proportions achieving control appeared higher in the post-surgery compared with the de-novo setting with pasireotide, but more similar with octreotide. Using pooled data from multicenter clinical trials, we examined the biochemical efficacy of lanreotide depot/Autogel in similar settings...
January 22, 2018: Pituitary
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"